Qiagen
QGEN · NYSE
Bulios Fair Price
$38.85
11.2% downside
Current Price
$43.75
According to Bulios Fair Price, QGEN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Qiagen N.V. (QGEN) is a Dutch company specializing in providing innovative diagnostic tests and technologies in the field of molecular biology. With a broad portfolio of products and services including tests for genetic mutations, infectious disease diagnostics, and analytical tools for genetic material research, Qiagen is one of the leading providers of diagnostic solutions in the market. The company focuses on providing accurate, reliable, and fast diagnostic tests that assist physicians and researchers in identifying and treating diseases. Qiagen also invests in innovation and the development of new diagnostic technologies to continuously improve patient diagnosis and treatment. Qiagen N.V. (QGEN) shares could be suitable for investors looking to invest in biotechnology companies with a focus on molecular diagnostics and innovative research and development in the healthcare sector.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Jon Pratt
Employees
5,500
Headquarters
Venlo
Upcoming events
Earnings
Upcoming earnings report